by Jordana Choucair | Nov 29, 2022 | M&A
AstraZeneca PLC announced it will acquire Neogene Therapeutics Inc. in a deal worth up to $320 million, growing the company’s oncology portfolio. The transaction is expected to close in the first quarter of 2023, subject to customary closing conditions and...
by Jordana Choucair | Nov 29, 2022 | M&A
Boston Scientific announced it entered a definitive agreement to acquire Apollo Endosurgery for a cash price of $10 per share to reflect an enterprise value of approximately $615 million. Apollo Endosurgery anticipates net sales of approximately $76 million in the...
by Jordana Choucair | Nov 21, 2022 | M&A
The Department of Justice (DOJ) and two states – New York and Minnesota – issued a notice to appeal a judge’s decision to dismiss their antitrust challenge of UnitedHealth’s acquisition of Change Healthcare. The DOJ sued to block the deal in February,...
by Jordana Choucair | Nov 21, 2022 | M&A
Merck & Co. agreed to acquire cancer developer Imago BioSciences Inc. in a deal valued at $1.35 billion. The deal will add new revenue streams as Merck’s patent deal for cancer treatment Keytruda is set to expire early next year and grow its presence in the...
by Jordana Choucair | Nov 16, 2022 | M&A
South Dakota-based Sanford Health and Minnesota-based Fairview Health Services unveiled plans Tuesday to merge and form $14 billion health system serving rural and urban patients across the Midwest. The merger would give Sanford Health access to a major metropolitan...
by Jordana Choucair | Nov 14, 2022 | M&A
A Kaiser Health News (KHN) investigation found that private equity’s increasing presence in health care has resulted in higher prices, decreased quality of care, lawsuits, and complaints about care. According to PitchBook, private equity firms invested $206 billion in...
Recent Comments